This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
IL-35 Agonist (Tizona)
Tizona Therapeutics, Inc.
Drug Names(s): IL-35 Agonist
Description: Tizona is developing an IL-35 agonist for the treatment of autoimmune diseases. IL-35 is an immunosuppressive cytokine, predominantly expressed by Tregs. IL-35 is involved in suppression of anti-tumor immunity through its modulation of effector T cells, as well as myeloid cells. Blocking IL-35’s activity may reverse immune suppression in the tumor microenvironment and lead to a robust and effective anti-tumor immune response.
IL-35 Agonist (Tizona) News
Additional information available to subscribers only: